(Q58448872)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 August 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

Trends in Endocrinology and Metabolism

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

229-235

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

Exon duplication and divergence in the human preproglucagon gene

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

The biological significance of "enteroglucagon." Present status

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

1 reference

7 January 2021

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Ileal release of glucagon-like peptide-1 (GLP-1)

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Gastric emptying and release of incretin hormones after glucose ingestion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-like peptide-1 is a physiological incretin in rat

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

GLP-1 does not acutely affect insulin sensitivity in healthy man

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-like peptide-1: a potent regulator of food intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Attenuated GLP-1 secretion in obesity: cause or consequence?

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

The U.K. Prospective Diabetes Study. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900157-5

7 January 2021

10.1016/S1043-2760(99)00157-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10407397%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference